OKYO Pharma director buys 3,500 Nasdaq shares

OKYO Pharma Limited reported that Chief Development Officer and Director Gary S. Jacob, PhD purchased 3,500 of the company’s ordinary shares on Nasdaq at $1.40 per share, increasing his total holdings to 112,420 ordinary shares.

Accepted by SEC EDGAR 07/22/2026 - 10:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Limited reported that Chief Development Officer and Director Gary S. Jacob, PhD purchased 3,500 of the company’s ordinary shares on Nasdaq at $1.40 per share, increasing his total holdings to 112,420 ordinary shares.

The clinical-stage biopharmaceutical company develops therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Key Figures

Shares purchased: 3,500 ordinary shares Purchase price: $1.40 per share Total insider holdings: 112,420 ordinary shares +1 more

4 metrics

Shares purchased 3,500 ordinary shares Ordinary shares purchased on Nasdaq by Chief Development Officer and Director Gary S. Jacob, PhD

Purchase price $1.40 per share Price paid per ordinary share in the insider purchase on Nasdaq

Total insider holdings 112,420 ordinary shares Holdings of Gary S. Jacob, PhD after completing the reported purchase

Planned Phase 3 enrollment approximately 111 patients Expected enrollment for global Phase 3 pivotal urcosimod trial in neuropathic corneal pain

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

urcosimod medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO (OKYO) disclose?

OKYO Pharma disclosed that Gary S. Jacob, PhD, Chief Development Officer and Director, bought 3,500 ordinary shares at $1.40 per share on Nasdaq. This transaction increased his holdings to 112,420 ordinary shares, according to the July 22, 2026 announcement.

How many OKYO (OKYO) shares does Gary S. Jacob now hold after the purchase?

After the reported transaction, Gary S. Jacob, PhD holds a total of 112,420 OKYO Pharma ordinary shares. This reflects the addition of 3,500 shares purchased on Nasdaq at $1.40 per share as described in the company’s announcement.

What is OKYO (OKYO) developing as its main therapeutic focus?

OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. Its programs include the investigational drug urcosimod, which is planned to be evaluated in a pivotal Phase 3 clinical trial for NCP.

What Phase 3 trial is OKYO (OKYO) planning to start?

OKYO plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for neuropathic corneal pain in the second half of this year. The study is expected to enroll approximately 111 patients using a single-dose treatment regimen.

On which market are OKYO (OKYO) ordinary shares listed and traded?

OKYO Pharma’s ordinary shares are listed for trading on the Nasdaq Capital Market. The reported insider purchase of 3,500 ordinary shares by Gary S. Jacob, PhD, was executed on Nasdaq at a price of $1.40 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 22, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date:  July 22, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 22, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.6 KB
• EX-99 GRAPHIC 22.7 KB